Developing anti-helminth vaccines for people and cattle: (For)seeing the health approach in action.
作者信息
Tendler Miriam, Savino Wilson, Almeida Marilia Sirianni Dos Santos
机构信息
Laboratory of Anti-Helminth Vaccine Research and Development, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
Laboratory on Thymus Research, Brazilian National Institute of Science and Technology on Neuroimmunomodulation, Rio de Janeiro Research Network on Neuroinflammation, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
出版信息
One Health. 2023 Aug 18;17:100616. doi: 10.1016/j.onehlt.2023.100616. eCollection 2023 Dec.
Abstract
摘要
相似文献
1
Developing anti-helminth vaccines for people and cattle: (For)seeing the health approach in action.开发用于人类和牛的抗蠕虫疫苗：见证实际应用中的健康方法。
One Health. 2023 Aug 18;17:100616. doi: 10.1016/j.onehlt.2023.100616. eCollection 2023 Dec.
2
The biotechnology-value chain: development of Sm14 as a schistosomiasis vaccine.生物技术价值链：Sm14作为血吸虫病疫苗的研发
Acta Trop. 2008 Nov-Dec;108(2-3):263-6. doi: 10.1016/j.actatropica.2008.09.002. Epub 2008 Sep 11.
3
Recombinant Mycobacterium bovis BCG expressing the Sm14 antigen of Schistosoma mansoni protects mice from cercarial challenge.表达曼氏血吸虫Sm14抗原的重组牛分枝杆菌卡介苗可保护小鼠免受尾蚴攻击。
Infect Immun. 2004 Jun;72(6):3336-43. doi: 10.1128/IAI.72.6.3336-3343.2004.
4
Stability improvement of the fatty acid binding protein Sm14 from S. mansoni by Cys replacement: structural and functional characterization of a vaccine candidate.通过半胱氨酸置换提高曼氏血吸虫脂肪酸结合蛋白Sm14的稳定性：一种候选疫苗的结构和功能表征
Biochim Biophys Acta. 2009 Apr;1794(4):655-62. doi: 10.1016/j.bbapap.2008.12.010. Epub 2008 Dec 25.
5
Co-administration of plasmid expressing IL-12 with 14-kDa Schistosoma mansoni fatty acid-binding protein cDNA alters immune response profiles and fails to enhance protection induced by Sm14 DNA vaccine alone.将表达白细胞介素-12的质粒与曼氏血吸虫14 kDa脂肪酸结合蛋白cDNA共同给药会改变免疫反应谱，并且无法增强单独使用Sm14 DNA疫苗诱导的保护作用。
Microbes Infect. 2006 Aug;8(9-10):2509-16. doi: 10.1016/j.micinf.2006.06.008. Epub 2006 Jul 24.
6
Combination of the two schistosomal antigens Sm14 and Sm29 elicits significant protection against experimental Schistosoma mansoni infection.两种血吸虫抗原 Sm14 和 Sm29 的联合使用可显著预防实验性曼氏血吸虫感染。
Exp Parasitol. 2014 Oct;145:51-60. doi: 10.1016/j.exppara.2014.07.010. Epub 2014 Aug 1.
7
Sm14 gene expression in different stages of the Schistosoma mansoni life cycle and immunolocalization of the Sm14 protein within the adult worm.曼氏血吸虫生命周期不同阶段的Sm14基因表达及成虫体内Sm14蛋白的免疫定位。
Braz J Med Biol Res. 2002 Mar;35(3):377-81. doi: 10.1590/s0100-879x2002000300014.
8
Fusion protein comprised of the two schistosomal antigens, Sm14 and Sm29, provides significant protection against Schistosoma mansoni in murine infection model.由两种血吸虫抗原Sm14和Sm29组成的融合蛋白，在小鼠感染模型中对曼氏血吸虫提供了显著的保护作用。
BMC Infect Dis. 2015 Mar 24;15:147. doi: 10.1186/s12879-015-0906-z.
9
Sm14 of Schistosoma mansoni in fusion with tetanus toxin fragment C induces immunoprotection against tetanus and schistosomiasis in mice.曼氏血吸虫的Sm14与破伤风毒素片段C融合可诱导小鼠对破伤风和血吸虫病产生免疫保护。
Infect Immun. 2004 Oct;72(10):5931-7. doi: 10.1128/IAI.72.10.5931-5937.2004.
10
Human T cell epitope mapping of the Schistosoma mansoni 14-kDa fatty acid-binding protein using cells from patients living in areas endemic for schistosomiasis.利用血吸虫病流行地区患者的细胞对曼氏血吸虫14 kDa脂肪酸结合蛋白进行人T细胞表位定位
Microbes Infect. 2005 Feb;7(2):204-12. doi: 10.1016/j.micinf.2004.10.012. Epub 2005 Jan 19.
本文引用的文献
1
Development of the Sm14/GLA-SE Schistosomiasis Vaccine Candidate: An Open, Non-Placebo-Controlled, Standardized-Dose Immunization Phase Ib Clinical Trial Targeting Healthy Young Women.Sm14/GLA-SE血吸虫病候选疫苗的研发：一项针对健康年轻女性的开放、非安慰剂对照、标准化剂量免疫的Ib期临床试验
Vaccines (Basel). 2022 Oct 15;10(10):1724. doi: 10.3390/vaccines10101724.
2
Covid-19 pandemic, R&D, vaccines, and the urgent need of UBUNTU practice.新冠疫情、研发、疫苗及践行“仁爱”的迫切需求
Lancet Reg Health Am. 2021 Sep;1:100020. doi: 10.1016/j.lana.2021.100020. Epub 2021 Jul 24.
3
Efficacy of a multivalent vaccine against Fasciola hepatica infection in sheep.多价疫苗对绵羊肝片吸虫感染的疗效。
Vet Res. 2021 Jan 28;52(1):13. doi: 10.1186/s13567-021-00895-0.
4
Schistosomiasis vaccine candidate Sm14/GLA-SE: Phase 1 safety and immunogenicity clinical trial in healthy, male adults.血吸虫病候选疫苗Sm14/GLA-SE：健康成年男性的1期安全性和免疫原性临床试验
Vaccine. 2016 Jan 20;34(4):586-594. doi: 10.1016/j.vaccine.2015.10.027. Epub 2015 Nov 10.
5
Immunomodulatory molecules of Fasciola hepatica: candidates for both vaccine and immunotherapeutic development.肝片吸虫的免疫调节分子：疫苗和免疫治疗开发的候选物
Vet Parasitol. 2013 Aug 1;195(3-4):272-85. doi: 10.1016/j.vetpar.2013.04.008. Epub 2013 Apr 6.
6
Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010.291 种疾病和伤害导致的伤残调整生命年（DALYs）在 21 个地区，1990-2010 年：全球疾病负担研究 2010 的系统分析。
Lancet. 2012 Dec 15;380(9859):2197-223. doi: 10.1016/S0140-6736(12)61689-4.
7
Evaluation of local immune response to Fasciola hepatica experimental infection in the liver and hepatic lymph nodes of goats immunized with Sm14 vaccine antigen.评价 Sm14 疫苗抗原免疫山羊后肝脏和肝淋巴结中对肝片形吸虫实验感染的局部免疫反应。
Mem Inst Oswaldo Cruz. 2010 Aug;105(5):698-705. doi: 10.1590/s0074-02762010000500017.
8
Understanding triclabendazole resistance.了解三氯苯达唑耐药性。
Exp Mol Pathol. 2007 Apr;82(2):104-9. doi: 10.1016/j.yexmp.2007.01.009. Epub 2007 Feb 15.
9
Vaccination against Fasciola hepatica infection using a Schistosoma mansoni defined recombinant antigen, Sm14.使用曼氏血吸虫特定重组抗原Sm14对肝片吸虫感染进行疫苗接种。
Parasite Immunol. 2003 Mar;25(3):135-7. doi: 10.1046/j.1365-3024.2003.00619.x.
10
Schistosomiasis: from risk assessment to control.血吸虫病：从风险评估到控制
Trends Parasitol. 2002 Jul;18(7):309-14. doi: 10.1016/s1471-4922(02)02301-2.
Zotero 插件